<DOC>
	<DOCNO>NCT00148850</DOCNO>
	<brief_summary>The aim randomize study compare effect pioglitazone versus placebo change limb fat HIV 1-infected patient treated antiretroviral therapy least 6 month clinical lipoatrophy .</brief_summary>
	<brief_title>Effect Pioglitazone HIV-1 Related Lipoatrophy : Randomized , Double Blind , Placebo-Controlled Trial 130 Patients</brief_title>
	<detailed_description>Lipodystrophy one frequent treatment side effect HIV-1 infect patient . This complication stigmatize affected patient lead reduce adherence treatment , increase risk cardiovascular complication induce insulinoresistance . The pathophysiology lipodystrophy remain poorly understood . Some antiretroviral drug could involve . Therefore , use PPAR G therapeutic target objective reverse drug induce lipoatrophy appear promising objective Thiazolidinediones new class insulin sensitize drug treatment type 2 diabetes . These PPARG agonist mainly promote differentiation adipocytes , decrease circulate plasma free fatty acid . In non-HIV infected patient class drug decrease intraabdominal fat accumulation increase subcutaneous fat depot . Different previous study perform aim , use rosiglitazone . We design prospective randomize , double blind placebo control multicentre study aim test hypothesis pioglitazone would improve lipoatrophy without deleterious effect lipid profile adult subject receive antiretroviral therapy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>HIV-Associated Lipodystrophy Syndrome</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>18 year age old Confirmed laboratory diagnosis HIV1infection – Karnofsky equal 70 % Patients treat stable antiretroviral therapy least 6 month Plasma viral load 400 copies/ ml CD4 count 200/mm3 least 6 month Patients clinical peripheral lipoatrophy self report patient confirm physical examination Cachexia Cardiac failure class3 4 NYHA classification Acute opportunistic infection Pregnancy breastfeed Polynuclear neutrophils 1000/mm3 Hemoglobin 9 g/dl Platelets 50 000/mm3 – Creatinine level 2 UN ASAT , ALAT 2.5UN Bilirubin , amylase , lipase level 2 UN CD4 count 200/mm3 Patients treat antidiabetic lipid lower drug , anabolic corticosteroid hormone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>HIV-Associated Lipodystrophy Syndrome</keyword>
	<keyword>pioglitazone</keyword>
	<keyword>HIV infection</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>